Five Applications Per Day and Karplus Account Rules
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The Karplus system imposes three hard constraints on filing cadence (Annex I, Article 5, of RA 0007/2025): each declarant may submit at most 5 applications per day for registration (item l, covering new registrations, renewals and post-registration changes without distinguishing between them); accounts may not be lent to third parties (item i, the holder being responsible for everything done under the account); and no new application may be filed while one is already in progress for the same registration or establishment (item m). The system is open only on working days from 8:00 to 17:00, and corrections following a rejection must be completed within that window (items n and o).
2. Legal basis
All three constraints appear in a single article of Annex I, alongside the rules on who may operate an account. The key provisions are set out below.
| Level | Instrument | Provision | Key point |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 5, item l | A declarant may submit at most 5 registration applications per day (new registration, renewal or post-registration change), with no distinction by application type |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 5, item i | The holder of a Karplus account may not allow a third party to use it and is responsible for any action carried out under the account |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 5, item m | Where an application is already in progress for the same registration or establishment, no new application may be filed for it until that application is concluded |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 5, item n | System processing is available only on working days from 8:00 to 17:00 |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 5, item o | Corrections of a registration rejection are made by the applicant on working days within the hours above |
| Administrative decision | Administrative Resolution No. 0007/2025 (in force from 2025-05-02) | Annex I, Article 5, items f, g and h | Processing must be carried out by a regente sanitario or registrador holding a Karplus account; the account must be applied for using the official form; modules of other directorates already activated must be declared |
3. Expert insights
Insight 1: the quota of 5 is counted per person per day, not per company per day. The subject of item l is «El registrador». If a single company has several registradores holding accounts, in theory each has their own quota; but item i forbids lending accounts, so the quotas cannot be pooled by sharing a login. Filing capacity therefore depends on the number of natural persons holding accounts, not on the size of the company.
Insight 2: item m is the provision most often misread as one matter per day. It restricts applications related to the same registration or establishment — «relacionado con ese registro sanitario o establecimiento». Registrations for different products may still be filed in parallel on the same day, provided the cap of 5 is respected. Reading item m as a global serialization artificially lengthens project timelines.
Insight 3: item i establishes strict liability. The text states that the holder «es responsable de cualquier acción que se realice mediante la utilización de su usuario Karplus» — is responsible for any action carried out through the use of the Karplus account. This makes account management a compliance matter rather than an IT matter: when staff leave or an agent is replaced, the handover must be documented, not merely accompanied by the return of a password.
Insight 4: read together with item h, accounts are reused across modules. Item h requires professionals who already hold a Karplus account with modules of other ANRS directorates to declare this when applying. The same person may hold both a pharmaceutical and a device module, and whether the quota of 5 is aggregated across modules is not stated — this volume treats the point as not stated and recommends written confirmation from the DDM.
Insight 5: deadlines stack on top of opening hours, so the real window is narrower than the text suggests. Item n restricts system availability to working days from 8:00 to 17:00, and item o requires corrections after a rejection to be completed within that window. A cross-timezone team that does not convert the hours will systematically lose a day from the 15 or 20 working days available.
Insight 6: the consequences of breach are not set out in a dedicated penalty provision. Article 18 of Annex I refers only in general terms to Ley 1068 and Ley 423 and their regulations; how the three hard constraints are actually enforced — by system blocking or by manual determination — is not stated in the text. This volume therefore does not assume automatic blocking and treats the constraints as matters of self-compliance.
4. Practical recommendations
- Plan filing capacity on the number of natural persons holding accounts rather than on headcount, and never share an account.
- Read item m as serialization per registration or establishment: renewal and change of the same product do not run in parallel, while registrations for different products may.
- Establish a documented account handover procedure: when staff leave or an agent is replaced, record in writing when the account was returned and when responsibility transferred.
- Confirm in writing with the DDM whether the quota of 5 is aggregated across Karplus modules, rather than making an assumption.
- Convert correction deadlines into Nicaraguan local working hours and submit by the previous working day.
- Where a failure occurs outside system hours, notify by email under item r of Article 5 with screenshots attached, and keep the transmission records.
5. Verification checklist
- □ Planned the filing cadence on the number of natural persons holding accounts, with no account sharing
- □ Ordered submissions on the basis of serialization per registration or establishment and parallel filing for different products
- □ Established a documented account handover procedure
- □ Requested written confirmation from the DDM on whether the quota of 5 is aggregated across modules
- □ Converted correction deadlines into Nicaraguan local working hours and submitted one day in advance
- □ Reported system failures by email under item r of Article 5, retaining screenshots and transmission records
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Nicaraguan market. Our team manages Ministry of Health (MINSA) sanitary registration applications, prepares Spanish-language dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us